PARIS, FRANCE: Theradiag, a company specializing in in vitro diagnostics and Theranostics, announced the launch of a rights issue for a target amount of €5.3 million issuing 4.37 million shares at a price of €1.22 per share at a ratio of 1 new share for every 2 existing shares. Bertrand de Castelnau, CEO of Theradiag,…